Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy

T. Notake1, A. Shimizu1,*, K. Kubota1, T. Ikehara1, H. Hayashi1, K. Yasukawa1, A. Kobayashi1, A. Yamada2, Y. Fujinaga2 and Y. Soejima1

1Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan,
2Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan

*Correspondence to: Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan (e-mail: ashimizu@shinshu-u.ac.jp)

Abstract

Background: Functional assessment of the future liver remnant (FLR) after major hepatectomy is essential but often difficult in patients with biliary malignancy, owing to obstructive jaundice and portal vein embolization. This study evaluated whether a novel index using gadoxetate disodium-enhanced MRI (EOB-MRI) could predict posthepatectomy liver failure (PHLF) after major hepatectomy for biliary malignancy.

Methods: The remnant hepatocellular uptake index (rHUI) was calculated in patients undergoing EOB-MRI before major hepatectomy for biliary malignancy. Receiver operating characteristic (ROC) curve analyses were used to evaluate the accuracy of rHUI for predicting PHLF grade B or C, according to International Study Group of Liver Surgery criteria. Multivariable logistic regression analyses comprised stepwise selection of parameters, including rHUI and other conventional indices.

Results: This study included 67 patients. The rHUI accurately predicted PHLF (area under the curve (AUC) 0.896). A cut-off value for rHUI of less than 0.410 predicted all patients who developed grade B or C PHLF. In multivariable analysis, only rHUI was an independent risk factor for grade B or C PHLF (odds ratio 2.0^{103}, 95 per cent c.i. 19.6 to 3.8^{107}; P < 0.001). In patients who underwent preoperative portal vein embolization, rHUI accurately predicted PHLF (AUC 0.885), whereas other conventional indices, such as the plasma disappearance rate of indocyanine green of the FLR and FLR volume, did not.

Conclusion: The rHUI is potentially a useful predictor of PHLF after major hepatectomy for biliary malignancy.

Introduction

Posthepatectomy liver failure (PHLF) is a leading cause of life-threatening complications in patients who undergo liver resection1–6. In particular, almost all patients with biliary malignancy require major hepatectomy and also have heterogeneous liver parenchyma resulting from preoperative portal vein embolization (PVE) or unilateral biliary drainage. Therefore, accurate measurement of remnant liver function in these patients is essential, and more critical than measurement of total liver function, to avoid PHLF after major hepatectomy.

Various methods, such as CT volumetry and the indocyanine green (ICG) test, have been used for preoperative quantitative assessment of hepatic function7–10. Nagino and colleagues11–13 reported that the future liver remnant (FLR) plasma clearance rate of ICG (ICGK-F), which is calculated by combining the data from CT volumetry (for FLR volume, FLRV) and ICG clearance tests (for total liver function), was significantly associated with incidence of postoperative mortality. A recent study13 revealed that, even with these criteria (ICGK-F below 0.05), the incidence of grade B or C PHLF, as determined by the International Study Group of Liver Surgery (ISGLS), was approximately 20 per cent, and the mortality rate was 1.7 per cent. These data suggest that conventional methods may not be sufficient to accurately estimate remnant functional reserve because they cannot evaluate the heterogeneity of liver parenchyma. Therefore, a more accurate predictor of FLR function is needed.

Gadoxetic acid (Primovist®; Bayer-Schering, Berlin, Germany) is a gadolinium-based paramagnetic contrast agent used in MRI of the liver14. Gadoxetate disodium is taken up by the hepatocytes via the same transport mechanism as bilirubin. Several
studies have reported that gadoxetate disodium-enhanced MRI (EOB-MRI) should provide information for the quantitative evaluation of liver function. Yamada and co-workers previously reported that the hepatocellular uptake index (HUI) obtained by EOB-MRI facilitated quantitative estimation of liver function and correlated well with the ICG clearance test. The HUI is calculated directly from the FLR, which implies that assessment using this index is more accurate for quantification of FLR function, especially in patients with regional liver heterogeneity.

Several studies have reported that parameters determined from preoperative EOB-MRI could predict PHLF. Remnant HUI (rHUI) is also reported to be a useful predictor of PHLF in patients with hepatocellular carcinoma. However, the main subjects of these studies were patients with colorectal liver metastasis or hepatocellular carcinoma; whether EOB-MRI can usefully predict PHLF in patients with biliary malignancy, in whom regional heterogeneity of the liver is common, remains to be elucidated. The purpose of this study was to evaluate whether rHUI can predict PHLF in patients undergoing major hepatic resection for biliary malignancy.

Methods

This retrospective study was approved by the Institutional Review Board of Shinshu University (no. 4562), and the requirement for informed consent was waived. The study included patients who underwent major hepatectomy for biliary malignancy between January 2010 and December 2019. Major hepatic resection was defined as a resection involving three or more Couinaud’s segments. Exclusion criteria were: lack of preoperative MRI within 8 weeks, significant cholestasis (bilirubin level over 2.0 mg/dl) at the EOB-MRI examination, and reoperation within 3 days of surgery.

Preoperative management

Patients with clinical jaundice received preoperative biliary drainage (PBD), with either endoscopic retrograde or percutaneous transhepatic biliary drainage. PBD is usually performed unilaterally on the future remnant hemiliver side. If scheduled liver resection encompassed more than 60 per cent of the total liver parenchyma, as calculated from serial CT images, preoperative PVE was indicated and scheduled once the serum total bilirubin level had decreased to below 5 mg/dl. The resection was planned 2–3 weeks after PVE, provided that hypertrophy of the FLR (more than 40 per cent of total liver volume) had been confirmed by successive CT scans, and the serum total bilirubin level had dropped to below 2 mg/dl.

MRI protocol

Preoperative imaging of the entire liver and spleen was performed 20 min after intravenous administration of 0.025 mmol per kg gadoxetate disodium. Single-breathhold three-dimensional gradient-echo images with fat suppression were obtained (repetition time 3 ms, echo time 1.23 ms, flip angle 14°, slice thickness 3 mm, pixel spacing approximately 1 × 1 mm with various fields of view and image matrices) on a 3.0-T MRI system (Trio Tim, Siemens, Germany) with eight channels in a phased-array body coil. A parallel-imaging technique was used (acceleration factor 2).

Image analysis

Outlines of the FLR and spleen on every slice of preoperative MRI were determined by a board-certified liver surgeon (18 years of experience in liver surgery) and a board-certified radiologist (20 years of experience in diagnostic imaging) with the use of a semi-automatic segmentation tool, developed by MATLAB R2018a (MathWorks, Natick, Massachusetts, USA) (Fig. 1). In the procedure to determine the cutting line for hepatectomy, postoperative contrast-enhanced CT or MRI images were used as reference. The volume (V) and mean signal intensity of the FLR (rL20) and spleen (S20) on preoperative MRI were obtained within the volume included in the outlines. Signal intensities were normalized to maximum signal intensity in all images for each patient. The intraclass correlation coefficient was evaluated for observer concordance of features obtained. From these values obtained by EOB-MRI, rHUI was calculated as: \( rV/R = \frac{V \times (rL20/S20) - 1)}{1} \).

Estimation of future liver remnant volume

FLR volume (FLRV) was estimated on the basis of Digital Imaging and Communications in Medicine data from CT using three-dimensional volumetry software (Organs Volume Analysis; Hitachi Medical Corporation, Chiba, Japan). The phase in which the liver border was most clearly shown was used in the analyses. The FLR proportion was calculated as the proportion of FLRV to total liver volume. The CT protocol was as follows. The entire liver was imaged on a 64-row CT scanner (Light Speed VCT; GE Healthcare, Little Chalfont, UK). The precontrast phase and nine phases after injecting the intravenous contrast agent were scanned: seven at 6-s intervals, beginning 22 s after injection, and one each at 90 and 210 s after injection. Imaging parameters were: range 25 cm caudal to the upper level of the diaphragm; tube voltage 120 kVp; tube current 300 mA (phases 2–8 and 10) or 500 mA (phases 1 and 9); matrix 512 × 512 pixels; field of view 320 × 320 mm; size of collimation 0.625 mm; reconstruction thickness 2.5 mm. The median effective dose was 48.9 (i.q.r. 48.2–48.9) mSv. A non-ionic iodinated contrast agent (Iopamiron® 370 mg/ml; Bayer Healthcare, Berlin, Germany) was administered intravenously through a 22G catheter in the median cubital vein. The total dose was 100 ml, and the rate of injection 3 ml/s.

Preoperative and intraoperative data

As preoperative liver function tests, the following serum measurements were recorded: total bilirubin, albumin, aspartate aminotransferase, alanine aminotransferase, prothrombin time, and platelet count. The Child–Pugh grade was calculated and recorded. The preoperative plasma clearance rate of ICG (ICGK) was derived from ICG clearance testing, as described previously. The ICGK-F was calculated as ICGK × FLR proportion. Other intraoperative parameters recorded were duration of operation, blood loss, red blood cell transfusion, and total duration of clamping.

Definition of posthepatectomy liver failure

PHLF was defined according to the criteria proposed by the ISGLS, comprising increased international normalized ratio (INR) and concomitant hyperbilirubinemia on day 5 after surgery. The INR cut-off values for prothrombin time and serum bilirubin concentration at this institution were 1.15 and 1.40 mg/dl respectively. Patients with PHLF were further classified into three groups according to severity of liver failure. Grade A PHLF is defined as postoperative impairment of liver function that does not require a change in the patient’s clinical management, which can be accomplished without deviation from the typical postoperative pathway. Grade B PHLF is defined by a deviation from the regular course, but not requiring invasive therapy. The criteria for grade C PHLF include the need for invasive treatment, such as
haemodialysis, intubation and mechanical ventilation, extracorporeal liver support, rescue hepatectomy, and transplantation.

**Statistical analysis**

Categorical data are presented as numbers with percentages, and continuous variables as median (range). The diagnostic accuracy of MRI parameters for grade B or C PHLF was calculated by means of receiver operating characteristic (ROC) curve analyses, and area under the curve (AUC) was calculated. Multivariable logistic regression analysis was conducted by a stepwise procedure using the minimum Akaike’s information criterion method among the conventional preoperative liver function indicators, including EOB-MRI-related parameters. If data separation occurred in logistic regression analysis, odds ratios and 95 per cent confidence intervals were calculated using Firth’s bias-reduced logistic regression analysis to evaluate the risk of grade B or C PHLF. Cut-off values for each variable were determined to minimize the Youden index using ROC curve analysis. Odds ratios were calculated to assess associations between cut-off values and occurrence of grade B or C PHLF. \( P < 0.050 \) (2-sided) was considered significant. Statistical analyses were performed using JMP® version 14.0 (SAS Institute, Cary, North Carolina, USA).

**Results**

Of 94 patients who underwent major hepatectomy for biliary malignancy between January 2010 and December 2019, 67 were included in this study (Fig. 2). Clinical and surgical data are summarized in in Tables 1 and 2. There were 40 men and 27 women with median age of 71 (range 42–88) years. For preoperative management, PVE was performed in 19 patients (28 per cent), and biliary drainage in 48 (72 per cent). The liver resections were right hemihepatectomy (35, 52 per cent), left hemihepatectomy (27, 40 per cent), right or left trisectionectomy (4, 6 per cent), and central bisectionectomy (1, 1 per cent). Most patients required biliary reconstruction. Pancreatoduodenectomy was performed simultaneously with hepatectomy in 11 patients (16 per cent). The median duration of operation was 657 min, with median blood loss of 610 ml. Blood transfusion was performed in five patients (9 per cent) during the operation.

Among the 67 enrolled patients, 27 (40 per cent) met the criteria for PHLF: grade A in 19 patients (28 per cent) and grade B or C in eight (12 per cent), including two patients with grade C PHLF. The mortality rate of 3 per cent apply to the whole cohort of 67 patients. Among preoperative factors, total bilirubin \((P = 0.003)\), prothrombin time \((P = 0.018)\), ICGK \((P = 0.020)\), ICGK-F \((P < 0.001)\), and FLRV \((P < 0.001)\) differed significantly between patients with and without grade B or C PHLF (Table 1).
### Table 1 Background characteristics of study population according to development of posthepatectomy liver failure

| Background data                        | Overall (n = 67) | Grade B or C PHLF | p‡  |
|----------------------------------------|------------------|-------------------|-----|
| **Age (years)**                        | 71 (42–88)       | 72 (59–81)        | 71 (42–88) | 0.641† |
| **Sex ratio (M : F)**                  | 40 : 27          | 7 : 1             | 33 : 26    | 0.087 |
| **BMI (kg/m²)**                        | 21.9 (15.0–30.7) | 19.5 (16.7–24.2)  | 22.2 (15.0–30.7) | 0.012‡ |
| **Child–Pugh grade**                   |                  |                   |   |  |
| A                                      | 66 (99)          | 7 (88)            | 59 (100)   |   |
| B                                      | 1 (1)            | 1 (12)            | 0 (0)      |   |
| C                                      | 0 (0)            | 0 (0)             | 0 (0)      |   |
| **Preoperative management**            |                  |                   |   |  |
| **Portal vein embolization**           |                  |                   |   |  |
| Yes                                    | 19 (28)          | 5 (63)            | 14 (24)    | 0.035 |
| No                                     | 48 (72)          | 3 (37)            | 45 (76)    |   |
| **Biliary drainage**                   |                  |                   |   |  |
| Yes                                    | 48 (72)          | 8 (100)           | 40 (68)    | 0.093 |
| No                                     | 19 (28)          | 0 (0)             | 19 (32)    |   |
| **Preoperative blood tests**           |                  |                   |   |  |
| **Total bilirubin (mg/dl)**            | 0.70 (0.21–2.15) | 0.91 (0.70–2.15)  | 0.66 (0.21–1.92) | 0.003‡ |
| AST (units/l)                          | 33 (9–99)        | 29 (16–57)        | 33 (9–99)  | 0.529† |
| ALT (units/l)                          | 45 (7–227)       | 40 (17–227)       | 45 (7–206) | 0.504† |
| Albumin (g/dl)                         | 3.6 (2.8–4.6)    | 3.4 (2.8–4.1)     | 3.7 (2.8–4.6) | 0.086‡ |
| Prothrombin time (%)                   | 90.2 (71.1–130.0)| 79.9 (75.6–92.2)  | 90.6 (71.1–130.0) | 0.018‡ |
| Platelet count (×10⁴/µl)              | 22.9 (8.4–48.6)  | 26.7 (13.6–45.3)  | 22.7 (8.4–48.6) | 0.219‡ |
| ICGK*                                  | 0.18 (0.10–0.28) | 0.15 (0.10–0.22)  | 0.18 (0.12–0.28) | 0.020‡ |
| ICGK-F*                                | 0.09 (0.04–0.16) | 0.06 (0.04–0.08)  | 0.09 (0.06–0.16) | < 0.001† |
| **CT volumetry-related parameters**   |                  |                   |   |  |
| FLRV (ml)*                             | 514 (336–1208)   | 379 (336–510)     | 536 (353–1208) | < 0.001‡ |
| FLR proportion (%)*                    | 35 (40–87)       | 38 (37–50)        | 52 (35–87)  | 0.004‡ |

Values in parentheses are percentages unless indicated otherwise; *values are median (range). AST, aspartate aminotransferase; ALT, alanine aminotransferase; ICGK, plasma clearance rate of indocyanine green (ICG); ICGK-F, future liver remnant (FLR) plasma clearance rate of ICG, FLRV, FLR volume.

Table 2 Surgical data for study population according to development of posthepatectomy liver failure

| Type of hepatectomy                     | Overall (n = 67) | Grade B or C PHLF | p†  |
|----------------------------------------|------------------|-------------------|-----|
| Right hepatectomy                      | 35 (52)          | 7 (88)            | 28 (47) | 0.116 |
| Left hepatectomy                       | 27 (40.5)        | 0 (0)             | 27 (46) |   |
| Central hepatectomy                    | 1 (1.5)          | 0 (0)             | 1 (2)   |   |
| Right trisectionectomy                 | 1 (1.5)          | 0 (0)             | 1 (2)   |   |
| Left trisectionectomy                  | 3 (4.5)          | 1 (12)            | 2 (3)   |   |
| **Vascular reconstruction**            |                  |                   |   |  |
| Yes                                    | 8 (12)           | 2 (25)            | 6 (10)  | 0.241 |
| No                                     | 59 (88)          | 6 (75)            | 53 (90) |   |
| **Pancreatoduodenectomy**              |                  |                   |   |  |
| Yes                                    | 11 (16)          | 5 (63)            | 6 (10)  | 0.002 |
| No                                     | 56 (84)          | 3 (37)            | 53 (90) |   |
| **Duration of operation (min)**        | 657 (417–1297)   | 699 (556–1297)    | 653 (417–1215) | 0.155‡ |
| **Blood loss (ml)**                    | 610 (130–4000)   | 950 (300–2500)    | 570 (130–4000) | 0.039‡ |
| **Blood transfusion**                  |                  |                   |   |  |
| Yes                                    | 5 (7)            | 2 (25)            | 3 (5)   | 0.104 |
| No                                     | 62 (93)          | 6 (75)            | 56 (95) |   |
| **Total duration of clamping (min)**   | 55 (24–139)      | 61 (36–122)       | 55 (24–139) | 0.818‡ |

Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Continuous variables were compared using the Wilcoxon rank sum test, while categorical variables were compared using the χ² test or Fisher’s exact test as appropriate.

Wilkoxon rank sum test.
ROC analysis of rHUI for predicting grade B or C PHLF

ROC analyses were done to evaluate the predictive accuracy of rHUI. The AUC was 0.896 (95 per cent c.i. 0.760–0.959; P < 0.001) (Fig. 3). The cut-off value of rHUI for predicting grade B or C PHLF was determined as 0.410, with a sensitivity of 1.00 and specificity of 0.73. The incidence of PHLF according to level of rHUI is shown in Fig. 4. No patients with an rHUI value exceeding 0.410 developed grade B or C PHLF. Although some patients with an rHUI value greater than 0.410 had PHLF grade A, the incidence of PHLF of all grades was almost inversely proportional to the rHUI value (r = −0.743, P = 0.013). Several studies have reported that the parameters determined from EOB-MRI could predict PHLF in patients who underwent hepatectomy more accurately after adjusting for bodyweight (BW, kg) or body surface area (BSA, m²). However, neither BW nor BSA improved the accuracy of rHUI for predicting grade B or C PHLF in the present cohort (AUC for rHUI adjusted for BW 0.595, for rHUI adjusted for BSA 0.622) (Fig. S1).

Accuracy of rHUI compared with conventional parameters for predicting grade B or C PHLF

Table 3 summarizes the results of ROC analyses for predicting grade B or C PHLF. The AUC for rHUI was larger than those for any other conventional parameters generally used to select appropriate candidates for major hepatic resection.

Table 4 shows the results of univariable and multivariable analyses of the rHUI and other preoperative factors as predictors in univariable analysis, rHUI (P < 0.001), total bilirubin (P = 0.026), prothrombin time (P = 0.016), ICGK (P = 0.026), ICGK-F (P = 0.002), FLRV (P < 0.001), and FLR proportion (P = 0.001) were associated with development of grade B or C PHLF. These seven factors were included in a stepwise procedure to select appropriate variables for the predictive model. Multivariable stepwise selection analysis identified rHUI below 0.410 as the only factor associated with an increased risk of developing grade B or C PHLF (odds ratio 2.0 × 10⁻³, 95 per cent c.i. 19.6 to 3.8 × 10⁻³; P < 0.001).

Patients with preoperative portal vein embolization

Table 3 shows the results of the ROC analyses for predicting grade B or C PHLF in 19 patients with preoperative PVE. rHUI accurately predicted grade B or C PHLF (AUC 0.885, P = 0.006) in these patients. On the other hand, conventional parameters, such as ICGK-F (P = 0.102), FLRV (P = 0.222), and FLR proportion (P = 0.684), were less accurate predictors of grade B or C PHLF in patients with preoperative PVE.
Table 3 Area under the curve for remnant hepatocellular uptake index and other conventional parameters in all patients, and in those who had portal vein embolization

| Characteristic (ROC) curve analyses for predicting grade B or C posthepatectomy liver failure | AUC | P | AUC | P |
|-------------------------------------------------|-----|---|-----|---|
| rHUI                                            | 0.896 (0.760, 0.959) | < 0.001 | 0.885 (0.594, 0.976) | 0.006 |
| Total bilirubin (mg/dl)                         | 0.824 (0.638, 0.910) | 0.023 | 0.921 (0.673, 0.985) | 0.004 |
| Serum albumin (g/dl)                            | 0.685 (0.438, 0.858) | 0.081 | 0.657 (0.391, 0.950) | 0.381 |
| Prothrombin time (%)                           | 0.757 (0.567, 0.881) | 0.012 | 0.642 (0.316, 0.875) | 0.414 |
| ICGK                                            | 0.754 (0.502, 0.903) | 0.010 | 0.771 (0.309, 0.962) | 0.045 |
| ICGK-F                                          | 0.894 (0.724, 0.964) | < 0.001 | 0.685 (0.265, 0.929) | 0.102 |
| FLRV (ml)                                       | 0.870 (0.717, 0.947) | < 0.001 | 0.671 (0.322, 0.897) | 0.222 |
| FLR proportion (%)                              | 0.815 (0.650, 0.915) | 0.001 | 0.700 (0.319, 0.920) | 0.684 |

Table 4 Univariable and multivariable logistic regression analyses of risk factors for grade B or C posthepatectomy liver failure

| Characteristic | No. of patients | Univariable analysis | Multivariable analysis |
|----------------|-----------------|----------------------|------------------------|
|                |                 | Odds ratio | P          | Odds ratio | P |
| rHUI           | 0.081           | 6.4 × 10^3 (77.9, 1.1 × 10^8) | < 0.001 | 2.0 × 10^3 (19.6, 3.8 × 10^7) | < 0.001 |
| Total bilirubin (mg/dl) | 0.034 | 5.85 (1.08, 31.66) | 1.00 (reference) | 34.4 (5.0, 9.7 × 10^3) | 1.00 (reference) |
| Serum albumin (g/dl) | 0.037 | 2.61 (0.54, 12.63) | 1.00 (reference) | 2.47 |
| Prothrombin time (%) | 0.001 | 7.42 (1.50, 36.60) | 1.00 (reference) | 0.016 |
| ICGK           | 0.017           | 5.85 (1.08, 31.66) | 1.00 (reference) | 33.2 (5.0, 7.3 × 10^3) | 1.00 (reference) |
| ICGK-F         | 0.008           | 14.1 (1.69, 128.46) | 1.00 (reference) | 60.0 (4.0, 4.8 × 10^5) | 1.00 (reference) |
| FLRV volume (ml) | 0.001 | 14.7 (2.58, 83.65) | 1.00 (reference) | 0.002 |
| FLR proportion (%) | 0.001 | 25.9 (1.82, 139.27) | 1.00 (reference) | 0.001 |

Discussion

The results demonstrate that low rHUI based on EOB-MRI can be a useful predictor of PHLF grade B or higher in patients undergoing major heptectomy for biliary malignancy. The predictive AUC of rHUI was higher than those of conventional clinical and imaging parameters, such as ICGK-F, FLRV, and FLR proportion. In multivariable analysis, low rHUI was an independent predictor of PHLF.

Both CT volumetry and ICG tests are used for preoperative quantitative assessment of liver function. Additionally, hepatobiliary scintigraphy, such as 99mTc-labelled mebrofenin hepatobiliary scintigraphy and 99mTc-labelled galactosyl human serum albumin scintigraphy, is reportedly used as an image-based liver function test. Functional liver assessment using EOB-MRI is arguably superior to conventional liver function tests.
already in clinical use for several reasons. First, EOB-MRI is readily available, and does not require radioactive isotopes. Second, EOB-MRI is already used widely in most centers that specialize in hepatopancreatobiliary surgery, because it has remarkable tumor detection ability owing to its high tissue contrast and high spatial resolution. Third, accurate hepatectomy cutting lines can be planned easily from MRI because of the high resolution of vascular structures, which permits accurate estimation of FLR function. Finally, this novel method can be performed without special tests, such as ICG, which is rarely available in Western countries.

The contrast enhancement effect of gadoxetate disodium in the hepatobiliary phase was due to both uptake by hepatocytes and presence in the extracellular fluid space. Extracellular fluid volumes are reportedly similar in the liver and spleen. Therefore, the contrast enhancement effect should be corrected by the spleen’s signal intensity. Actually, HUI was reported as the factor most significantly correlated with ICGK among various signal intensity-based parameters from EOB-MRI. As parameters comparable to signal intensity-based variables, T1 relaxation time has been reported as an alternative tool for quantifying liver function. In the near future, prediction of PHLF might be further improved using novel MRI techniques, such as T1 relaxation time.

Obstructive cholestasis is often present before surgery in patients with biliary malignancy. EOB-MRI might be affected in patients with obstructive cholestasis, because gadoxetate disodium is taken up by hepatocytes via the same transport mechanism as bilirubin. Eleven patients were excluded from the present study owing to significant cholestasis (total bilirubin level over 2.0 mg/dl). In fact, the rHUI level among these 11 patients with significant cholestasis was significantly lower than that of the study cohort (median 0.360 versus 0.521; P = 0.019). These data indicate that concomitant cholestasis might influence gadoxetic acid uptake into hepatocytes, and biliary drainage is essential for accurate analysis of liver function using EOB-MRI.

This study has several limitations. It was a retrospective analysis, with a relatively small sample size and few patients who developed grade B or C PHLF. Further prospective studies with a larger cohort are required. The study included subjects with almost uniform backgrounds, and the cut-off value for rHUI calculated here may not be appropriate for patients with background liver disease. The results may reflect some selection bias, because participants were selected as candidates eligible for hepatectomy using conventional methods for liver function assessment such as CT volumetry and ICG tests. Despite these drawbacks, the authors believe that the results will be of interest to hepatobiliary surgeons because few reports have described the usefulness of EOB-MRI for evaluation of FLR function, especially in patients with liver heterogeneity, such as those who undergo unilateral biliary drainage or PVE.

Acknowledgements

This study received no funding. The authors thank M. Brunker, from Edanz Group (https://en-author-services.edanzgroup.com/ac), for editing a draft of this manuscript.

Disclosure. The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

References

1. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S et al. Hepatic insufficiency and mortality in 1059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204: 854–862.
2. Iguchi K, Hatano E, Yamanaka K, Tanaka S, Taura K, Uemoto S. Validation of the conventional resection criteria in patients with hepatocellular carcinoma in terms of the incidence of posthepatectomy liver failure and long-term prognosis. Dig Surg 2015; 32: 344–351.
3. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malagó M, Jalan R et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008; 28: 767–780.
4. Ribiero HS, Costa WL Jr, Diniz AL, Godoy AL, Herman P, Coudry RA et al. Extended preoperative chemotherapy, extent of liver resection and blood transfusion are predictive factors of liver failure following resection of colorectal liver metastasis. Eur J Surg Oncol 2013; 39: 380–385.
5. Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Kakisaka T et al. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. World J Surg Oncol 2012; 10: 107.
6. Ren Z, Xu Y, Zhu S. Indocyanine green retention test avoiding liver failure after hepatectomy for hepatolithiasis. Hepatogastroenterology 2012; 59: 782–784.
7. Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink Rj, Steiger B et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 2013; 257: 27–36.
8. Clavien PA, Petrowsky H, De Oliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545–1559.
9. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. The value of residual liver volume as a predictor of hepatic...
dysfunction and infection after major liver resection. Gut 2005;54:289–296
10. Yaprap O, Guler N, Altaca G, Dayangac M, Demirbas T, Akylidiz M et al. Ratio of remnant to total liver volume or remnant to body weight: which one is more predictive on donor outcomes? HPB 2012;14:476–82
11. Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006;243:364–372
12. Yokoyama Y, Nishio H, Ebata T, Igarashi T, Sugawara G, Nagino M. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 2010;97:1260–1268
13. Yokoyama Y, Ebata T, Igarashi T, Sugawara G, Mizuno T, Yamaguchi J et al. The predictive value of indocyanine green clearance in future liver remnant for posthepatectomy liver failure following hepatectomy with extrahepatic bile duct resection. World J Surg 2016;40:1440–1447
14. Häm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1999;195:785–792
15. Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic aniontransporters. Drug Metab Dispos 2010;38:1024–1028
16. Nishie A, Ushijima Y, Tajima T, Asayama Y, Ishigami K, Kakihara D et al. Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison between Technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol 2012;81:1100–1104
17. Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010;34:362–366
18. Yamada A, Haru T, Li F, Fujinaga Y, Ueda K, Kadoya M et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 2011;260:727–733
19. Asenbaum U, Kaczirek K, Ba-Ssalamah A, Ringl H, Schwarz C, Waneck F et al. Post-hepatectomy liver failure after major hepatic resection: not only size matters. Eur Radiol 2018;28:4748–4756
20. Costa AF, Tremblay St-Germain A, Abdolell M, S mood RL, Cleary S, Jhaveri KS. Can contrast-enhanced MRI with gadoxetic acid predict liver failure and other complications after major hepatic resection? Clin Radiol 2017;72:598–605
21. Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A. Liver failure after major liver resection: risk assessment by using preoperative gadoxetic acid-enhanced 3-T MR imaging. Radiology 2013;269:777–786
22. Cho SH, Kang UR, Kim JD, Han YS, Choi DL. The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study. Eur J Radiol 2011;80:195–200
23. Kim DK, Choi JI, Choi MH, Park MY, Lee YJ, Rha SE et al. Prediction of posthepatectomy liver failure: MRI with hepatocyte-specific contrast agent versus indocyanine green clearance test. AJR Am J Roentgenol 2018;211:580–587
24. Furusawa N, Kobayashi A, Yokoyama T, Shimizu A, Motoyama H, Miyagawa S. Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality. World J Surg 2014;38:1164–1176
25. Makuchii M, Thai BL, Takayasu K, Takayama T, Hosue T, Gunvens P et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990;107:521–527
26. Haegele S, Reiter S, Waneck D, Offensperger F, Pereyra S, Stremitzer S et al. Perioperative noninvasive indocyanine green-clearance testing to predict postoperative outcome after liver resection. PLoS One 2016;11:e0165481
27. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149:713–724
28. Heinz G, Schepmter M. A solution to the problem of separation in logistic regression. Stat Med 2002;21:2409–2419
29. Araki K, Harimoto N, Kubo N, Watanabe A, Igarashi T, Tsukagoshi M et al. Functional remnant liver volumetry using Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) predicts post-hepatectomy liver failure in resection of more than one segment. HPB (Oxford) 2020;22:318–327
30. Orimo T, Kamiyama T, Kamachi H, Shimada S, Nagatsu A, Asahi Y et al. Predictive value of gadoxetic acid enhanced magnetic resonance imaging for posthepatectomy liver failure after a major hepatectomy. J Hepatobiliary Pancreat Sci 2020;27:531–540
31. Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ et al. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med 2007;48:685–692
32. Satoh K, Yamamoto Y, Nishiyama Y, Wakabayashi H, Ohkawa M. 99mTc-GSA liver dynamic SPECT for the preoperative assessment of hepatocyte function. Ann Nucl Med 2003;17:61–67
33. Kötz B, West C, Saleem A, Jones T, Price P. Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. Mol Cancer Ther 2009;8:303–309
34. Haimari M, Verloot N, Zeman F, Fellner C, Nickel D, Lang SA et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep 2017;7:43347
35. Heye T, Yang SR, Bock M, Brosit K, Weigand K, Longerich T et al. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012;22:1224–1232